The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.
 
Yung-Jue Bang
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Merck Sharp & Dohme (Inst)
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Charles S. Fuchs
Consulting or Advisory Role - Agios; Bayer; Dicerna; Entrinsic Health; Five Prime Therapeutics; Genentech/Roche; Gilead Sciences; KEW; Lilly; Merck; Merrimack; Sanofi; Taiho Pharmaceutical
 
Talia Golan
No Relationships to Disclose
 
Ravit Geva
Honoraria - Bristol-Myers Squibb; Lilly; Medison; Novartis; Roche
Consulting or Advisory Role - Merck Sharp & Dohme; Novartis
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Ono Pharmaceutical
Research Funding - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; Merck Serono; Merck Sharp & Dohme; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Shadia Ibrahim Jalal
Research Funding - AstraZeneca/MedImmune
 
Christophe Borg
Honoraria - Amgen; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme
Consulting or Advisory Role - Merck; SERVIER
Research Funding - Roche (Inst)
 
Toshihiko Doi
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Novartis
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Array BioPharma; Five Prime Therapeutics; Sirtex Medical
Speakers' Bureau - Genentech
Research Funding - Biomarin (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Genentech
 
Jiangdian Wang
Employment - MSD RD China
 
Minori Koshiji
Employment - Merck
 
Rita P. Dalal
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Hyun Cheol Chung
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Sharp & Dohme; Quintiles; Taiho Pharmaceutical
Speakers' Bureau - Lilly; Merck Serono
Research Funding - GlaxoSmithKline; Lilly; Merck Sharp & Dohme